Prostate-Specific Antigen Level at Initiation of Hormonal Therapy After Prostate-Specific Antigen Failure Following Prostatectomy or Radiotherapy and Therapeutic Response

An elevated PSA level before the initiation of AST was significantly associated with a decreased chance of a PSA nadir of 0.2 ng/mL or less after 8 months of AST. Given the association between the PSA nadir after AST and prostate-cancer specific mortality, men with increasing PSA levels could be considered for Phase II and III clinical trials evaluating the effect of adding novel systemic therapies to AST on the interval to prostate-cancer specific mortality.